[Influence of the structure of synthetic gestagens on their binding to progesteron receptors in the endometrium].

Chemical modification of progesterone molecule leads to changes both in the gestagenic activity of new derivatives and in their specific binding with progesterone receptors. The passage from esters (acetomepregenole, butagest) to the corresponding OH-forms such as 17a-acetoxy-3b-hydroxy-6-methyl-pregna-4,6-dien-20-one (ABMP)is accompanied by an increase in the binding with progesterone receptors in vitro. The translocation of a double bond from endocyclic (N6-N7) to exocyclic position (methylene group at N6 in ABMP) has no significant effect on the ability to binding with progesterone receptors.

[The peculiarities of epilepsy in the menopause].

Twenty seven cases with the combination of epilepsy and menopause are presented. The menopause proved to be a critical period for epilepsy manifestation: in 44.4% women with epilepsy the disease onset was observed at the peri- and post-menopause period. The course of epilepsy during this period was less severe: the frequency of seizures increased in 7.4% and decreased in 33.3%, no changes in the frequency of seizures were observed in 59.3%. The severity of menopause syndrome was not correlated with duration and severity of epilepsy, 81.4% of patients had the mild severity of this syndrome. The reduction of bone density was found in most of women (85.2%). It implies that all patients with epilepsy and menopause should receive a prophylactic treatment to prevent osteopenia. About 18.6% of patients required the hormone replacement therapy but only 7.4% received it due to adverse effects.